Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-01-04
2011-01-04
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S001530, C435S007100, C514S002600, C530S350000
Reexamination Certificate
active
07862813
ABSTRACT:
The present invention relates to the treatment of immune system abnormalities that can be found in lethal human cancers and also in the progressive Human Immunodeficiency Virus Type 1 (HIV-1) infections and provides medicaments to correct abnormalities in a subject with cancer or HIV-1-infected subjects, in order to allow the immune system to fight the cancer or HIV-1 infections. The present invention also discloses multivalent polypeptides which specifically bind to and enable destruction and/or inactivation of immune cells that have CD11b and CD3 on their surface, therefore dissipating the deleterious effects of the CD11b+T cells.
REFERENCES:
patent: 5234816 (1993-08-01), Terstappen
patent: 5578704 (1996-11-01), Kim et al.
patent: 5652109 (1997-07-01), Kim et al.
patent: 5652110 (1997-07-01), Kim et al.
patent: 5654157 (1997-08-01), Kim
patent: 5658570 (1997-08-01), Newman et al.
patent: 5668003 (1997-09-01), Kim
patent: 5688681 (1997-11-01), Kim
patent: 5980894 (1999-11-01), Kim
patent: 6294167 (2001-09-01), Lindhofer et al.
patent: 6359126 (2002-03-01), Kim et al.
patent: 6369204 (2002-04-01), Kim et al.
patent: 6448075 (2002-09-01), Thomas et al.
patent: 6544749 (2003-04-01), Kim
patent: 2003/0134416 (2003-07-01), Yamanishi et al.
patent: 2004/0023377 (2004-02-01), Assenmacher et al.
patent: 2005/0123536 (2005-06-01), Law et al.
patent: 2006/0045881 (2006-03-01), Molldrem
patent: 2006/0234226 (2006-10-01), Fahner et al.
patent: 2007/0237779 (2007-10-01), Ledbetter et al.
The Encyclopedia of Molecular Biology; Blackwell Sciences Ltd., p. 1052 (1994)).
Lee et al., Structure, 3:1333-1340 (1995).
Chatila et al., J Cell Biol, 109:3435-3444 (1989).
Diamond et al., J Cell Biol, 120:545-556 (1993).
Bjork Jr. et al., “The clinical significance of CD8+ T cell subset abnormalities in common human malignancies”,Clinical and Applied Immunology Reviews2:141, 2002.
Damle et. al., “Soluble Antigen-Primed Inducer T Cells Activate Antigen-Specific Suppressor T Cells in the Absence of Antigen-Pulsed Accessory Cells: Phenotypic Definition of Suppressor-Inducer and Suppressor-Effector Cells”,J. Immunology132(2):644, 1984.
Kundu and Merigan, “Inverse relationship of CD8+ CD11+ suppressor T cells with human immunodeficiency virus (HIV)-specific cellular cytotoxicity and natural killer cell activity in HIV infection”,Immunology74:567, 1991.
Landay et al., “Characterization of a Phenotypically distinct subpopulation of leu-2+ cells that suppresses T Cell proliferative responses”,J. Immunology131(6):2757, 1983.
Platsoucas et al., “Abnormal T Lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies”,J. Immunology129(5):2305, 1982.
Clement, Loran T. et al, “Morphologic and Phenotypic Features of the Subpopulation of Leu-2 Cells That Suppresses B Cell Differentiation,”J. of Immunology, vol. 133, No. 5, pp. 2461-2467, 1984.
Bristol Lynn
DLA Piper (LLP) US
LandOfFree
Bi-specific monoclonal antibody (specific for both CD3 and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bi-specific monoclonal antibody (specific for both CD3 and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bi-specific monoclonal antibody (specific for both CD3 and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2629574